药物代谢酶在肿瘤耐药性中的研究进展

摘要/Abstract

摘要： 肿瘤化学治疗法是目前肿瘤治疗最常用且最有效的方法之一,而在肿瘤化疗过程中出现的耐药现象是导致化疗失败的主要原因。肿瘤耐药的产生机制复杂多样,其中药物代谢酶在肿瘤耐药的发生发展中也极为重要。目前研究显示,有多种药物代谢酶如I相代谢中的细胞色素P450酶、环氧合酶等,Ⅱ相代谢中的谷胱甘肽转移酶、葡萄糖醛酸转移酶、葡萄糖神经酰胺合成酶、还原型烟酰胺腺嘌呤二核苷酸磷酸(NADPH)依赖型醌还原酶等以及一类被称作Ⅲ相反应酶类的药物外排泵,如P-糖蛋白等与肿瘤多药耐药的发生密切相关。本文就近年来有关的药物代谢酶与肿瘤耐药的相关性研究作一综述。

关键词: 药物代谢酶, 肿瘤耐药, 肿瘤

Abstract: Tumor chemotherapy is one of the most commonly used and effective treatment in antitumor therapy, but drug resistance usually leads to tumor chemotherapy failure. Drug resistance of tumor is often caused by varied mechanisms, of which the drug metabolism enzymes play very important role. In recent years, researchers found that there were many kinds of drug metabolism enzymes related to drug resistance of tumor. Such as Phase I enzymes (cytochrome P450 enzymes, COX-2), PhaseⅡ enzymes(GST, UGT, GCS, NQO1), and Phase Ⅲ enzymes drug transporter protein. In this article, we reviewed the correlation between drug metabolism enzymes and drug resistance of tumor, in order to provide a new way for anti-tumor therapy.

Key words: Drug metabolism enzyme, Drug resistance, Tumor

中图分类号:

R969

周颖, 周芳, 吴晓兰, 王广基. 药物代谢酶在肿瘤耐药性中的研究进展[J]. 中国临床药理学与治疗学, 2010, 15(12): 1418-1427.

ZHOU Ying, ZHOU Fang, WU Xiao-lan, WANG Guang-ji. Roles of drug metabolism enzymes in drug resistance of tumor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1418-1427.

参考文献

[1] Van der Heuvel-Eibrink MM, Sonneveld P, Pieters R. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukenia [J]. Int J Clin Pharmacol Ther, 2000, 38(3):94-110.
[2] Galimberti S, Marchetti A, Buttita F, et al. Multidrug resistance related genes and p53 expression in human non small cell lung cancer[J]. Anticancer Res,1998,18(4C): 2973- 2976.
[3] Iscan M, Klaavuniemi T, Coban T, et al. The expression of P450 enzymes in human breast tumours and normal breast tissue[J]. Breast Cancer Res Treat ,2001,70(1):47-54.
[4] Brockdorff BL, Skouv J, Reiter BE, et al. Increased expression of cytochrome P4501A1 and 1B1 genes in anti-oestrogen-resistant human breast cancer cell lines[J]. Int J Cancer, 2000, 88(6):902-906.
[5] Horiguchi J, Takai H, Koibuchi Y, et al. Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer[J]. Br J Cancer, 2002, 86(2):222-225.
[6] Lo R, Burgoon L, Macpherson L, et al. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells[J]. Biochimicaet Biophysica Acta, 2010, 1799(5/6):469-479.
[7] Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1[J]. Cancer Res,1997, 57(14):3026-3031.
[8] Strassburg CP, Strassburg A, Nguyen N, et al. Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes(UGT1A, UGT2B) in human oesophagus[J]. Biochem J, 1999, 338(Pt 2): 489-498.
[9] Vences-Mejía A, Caballero-Ortega H, Dorado-González V, et al. Cytochrome P450 expression in rat gastric epithelium with intestinal metaplasia induced by high dietary NaCl levels[J]. Environ Toxicol Phar , 2005, 20:57-64.
[10] Kim JH, Sherman ME, Curriero FC, et al. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers[J]. Toxicol Appl Pharmacol, 2004, 199(3): 210-219.
[11] Troussaint C, Albin N, Massaad L, et al. Main drug-and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues[J]. Cancer Res,1993,53(19):4608-4612.
[12] Leclerc J, Tournel G, Ngangue ECN, et al. Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers[J]. Biochimie,2010, 92(3):292-306.
[13] Mungikar AM, Zingde SM, Advabr SH, et al. Mixed function oxidase enzymes in human normal granulocytes and chronic myeloid leukemia cells, I: Detection and Estimation[J]. Biochem Med,1983, 30(2):181-187.
[14] Nagai F, Hiyoshi Y, Sugimachi K, et al. Cytochrome P450(CYP) expression in human myeloblastic and lymphoid cell lines[J]. Biol Pharm Bull, 2002, 25(3):383-385.
[15] Ribrag V, Massaad L, Janot F, et al. Main drug-metabolizing enzyme systems in human non-Hodgkin's lymphomas sensitive or resistant to chemotherapy[J]. Leuk Lymphoma,1995,18(3/4): 303-310.
[16] Miyoshi Y, Ando A, Takamura Y, et al. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissue[J]. Int J Cancer,2002,97(1):129-132.
[17] Yao D, Ding S, Burchell B, et al. Detoxication of Vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance [J]. J Pharmacol Exp Ther, 2000, 294(1): 387-395.
[18] McFadyen MC, McLeod HL, Jackson FC, et al. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance[J]. Biochem Pharmacol, 2001, 62(2):207-212.
[19] Murray GI, McFadyen MC, Mitchell RT, et al. Cytochrome P450 CYP3A in human renal cell cancer [J]. Br J Cancer,1999,79(11/12):1836-1842.
[20] Crommentuyn KM, Schellens JH, van der Berg JD, et al. In vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide[J]. Cancer Treat Rev, 1998, 24(5): 345-366.
[21] Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype[J]. Curr Pharm Des, 2004, 10(6):647-657.
[22] Ziemann C, SchaferD, Rudell G, et al. The cyclooxygenase system participates in functional mdr1b overexpression in primary rat hepatocyte cultures[J]. Hepatology, 2002,35(3):579-588.
[23] McCarty MF, Block KI. Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy[J]. Integr Cancer Ther, 2006, 5(3):252-268.
[24] Huang DS, Shen KZ, Wei JF, et al. Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2 [J].World J Gastroenterol, 2005,11(2):204-207.
[25] Daemen T, Velinova M, Regts J, et al. Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat[J]. Hepatology, 1997,26(2):416-423.
[26] Etienne MC, Cheradame S, Fischel JL, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity[J]. J Clin Oncol ,1995,13(7):1663-1670.
[27] Ueda M, Kitaura K, Kusada O, et al. Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells[J]. Jpn J Cancer Res, 2000, 91(11):1185-1191.
[28] Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase [J]. Clin Cancer Res, 2000, 6(4):1322-1327.
[29] Takahashi T, Fujiwara Y, Yamakido M, et al. The role of glucuronidation in 7-ethyl-10- hydroxycamptothecin resistance in vitro[J]. Jpn J Cancer Res,1997, 88(12):1211-1217.
[30] Fan M, Chambers TC. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy[J]. Drug Resist Updat, 2001,4(4):253-267.
[31] Hour TC, Chen J, Huang CY, et al. Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines[J]. Anticancer Res, 2000, 20(5A): 3221-3226.
[32] Gurbuxani S, Zhou D, Simomin G, et al. Expressin of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India [J]. Ann Hematol, 1998, 76(5): 195-200.
[33] Den Boer ML, Pieters R, Kazemier KM, et al. Different expression of glutathione S-transferase α, μ and π in childhood acute lymphoblastic and myeloid leukaemia[J]. Br J Haematol, 1999, 104(2): 321-327.
[34] Kolesar JM, Pritchard SC, Kerr KM, et al. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue[J]. Int J Oncol, 2002, 21(5):1119-1124.
[35] Basu S, Brown JE, Flannigan GM, et al. Immunohistochemical analysis of NAD(P)H: quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy[J]. Int J Cancer, 2004, 109(5):703-709.
[36] Siegel D, Ross D. Immunodetection of NAD(P)H: quinone oxidoreductase 1 (NQO1) in human tissues[J]. Free Radic Biol Med, 2000, 29(3/4):246-253.
[37] Siegel D, Gibson NW, Preusch PC, et al. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells[J]. Cancer Res, 1990,50(23):7483-7489.
[38] Siegel D, Gibson NW, Preusch PC, et al. Metabolism of diaziquone by NAD(P)H: (quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells[J]. Cancer Res,1990, 50(22):7293-7300.
[39] Gouaze V, Yu JY, Bleicher RJ, et al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy[J]. Mol Cancer Ther, 2004, 3(5):633-639.
[40] Radin NS. Chemotherapy by slowing glucosphingolipid synthesis[J]. Biochem Pharmacol, 1999, 57(6) :589-595.
[40] Yeh JJ, Hsu NY, Hsu WH, et al. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer[J]. Lung, 2005, 183(3):177-183.
[42] Hsia TC, Lin CC, Wang JJ, et al. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression[J]. Lung, 2002, 180(3): 173-179.
[43] Chen Y, Tang Y, Wang MT, et al. Human pregnane X receptor and resistance to chemotherapy in prostate cancer[J]. Cancer Res, 2007, 67(21):10361-10367.
[44] Alfred HS, Johan WJ. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview[J]. Adv Deliv Rev,2003,55(1):3-29.
[45] Hsia TC, Lin CC, Wang JJ, et al. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein ormultidrug resistance-related protein expression[J]. Lung,2002,180(3):173-179.
[46] Borst P, Evers R, Kool M, et al. The multidrug resistance protein family[J]. Biochim Biophys Acta,1999,1461(2):347-357.
[47] Kawabata S, Oka M, Soda H, et al. Expression and functional analyses of breast cancer resistance protein in lung cancer[J]. Clin Cancer Res,2003,9(8):3052-3057.
[48] Kawabata S, Oka M, Shiozawa K, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells[J]. Biochem Biophys Res Commun, 2001,280(5):1216-1223.
[49] Potter GA, Patterson LH, Wanogho E, et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by cytochrome P450 enzyme CYP1B1[J]. Br J Cancer,2002, 86(5):774-778.
[50] Trapani V, Patel V, Leong CO, et al. DNA damage and cell cycle arrest induced by 2- (4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells[J]. Br J Cancer, 2003, 88(4):599-605.
[51] 贺全仁.人类细胞色素P450同工酶与药物代谢[J].中国临床药理学与治疗学,1997,2(4):307-310.